Enhanced antitumor effect of cytosine arabinoside given in a schedule dictated by kinetic studies in vivo.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004273:DNA, Neoplasm / Q000096:biosynthesis; D007700:Kinetics; D007939:Leukemia L1210 / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009363:Neoplasm Proteins / Q000096:biosynthesis; D009368:Neoplasm Transplantation; D013936:Thymidine / Q000378:metabolism; D013997:Time Factors; D014184:Transplantation, Homologous; D014316:Tritium
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D009363:Neoplasm Proteins; D003561:Cytarabine; D014316:Tritium; D013936:Thymidine